Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Is there a role for radiation to the primary mediastinal disease in metastatic thymic neuroendocrine carcinoma with the primary as the only residual disease after systemic therapy?
What dose would you use to treat?
Related Questions
How does neoadjuvant chemo-immunotherapy impact your decision on hypofractionation/dose fractionation for locally advanced NSCLC, now getting RT alone?
Is there a role for the addition of radiation to preoperative chemoimmunotherapy in NSCLC with limited N2 disease planned for surgery?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Under what circumstances, if any, would you wait on initiating a TKI for metastatic recurrence of a Stage III NSCLC which occurred while on consolidative durvalumab to minimize pneumonitis risk?
Can palliative radiation be used to treat recurrent malignant pleural effusion in NSCLC?
Would the presence of an SVC stent affect your decision to offer BID vs once-daily chemoradiation for SCLC?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
Do more fractionated regimens reduce severe toxicity over SBRT in patients with ILD and early-stage NSCLC?
How do you assess whether a patient will be a good DIBH candidate for lung or abdomen treatments?
In a patient who underwent cryoablation for early NSCLC, is there a role for giving preemptive further local therapy?